KPV Peptide Dosing Guide: Gut Health, Protocol & Safety (2026)

KPV is a three-amino-acid peptide (lysine-proline-valine) cut from the C-terminus of alpha-MSH. The research community most often discusses it for anti-inflammatory and gut-barrier work, particularly in inflammatory bowel disease (IBD) models.

What makes KPV unusual is that it can be used orally. Most peptides break down in the gut, but KPV is small and stable enough to be absorbed through a transporter called PepT1. This is why oral KPV protocols are common, especially for gut-focused research, while subcutaneous (SubQ) protocols are more common for systemic models.

Unlike melanotan-type peptides, KPV does not trigger pigmentation. It uses a different mechanism than the rest of alpha-MSH and skips melanocortin-receptor signaling.

This protocol page is for KPV dosing, vial mixing, and planning. For the broader research view, visit the KPV guide on how it may work, studies, safety notes, and legal status.

KPV has been discussed across three main routes: oral, subcutaneous (SubQ), and topical. The choice usually follows the research target. Oral is favored for gut-focused work because PepT1 transporters are concentrated in inflamed intestinal tissue. SubQ is favored for systemic anti-inflammatory models. Topical is sometimes compounded for localized skin-inflammation models.

No completed human dose-finding trial defines an official KPV dose. The ranges below come from preclinical extrapolation and community-derived planning notes, not from FDA labels or registered trials.

Reconstitution is the same step regardless of route. Even oral protocols often start from a reconstituted vial — the liquid is taken sublingually or with water on an empty stomach. The table below covers the most common 5 mg and 10 mg vial sizes at multiple BAC-water volumes.

KPV works differently from most anti-inflammatory compounds. Instead of broadly suppressing the immune system the way steroids do, it targets a specific inflammation switch inside cells. The mechanism is unusually well mapped for a peptide that has not been tested in humans.

PepT1 is a transporter on the surface of intestinal cells that moves di- and tripeptides from the gut into the cell. KPV is small enough to fit. Inflamed gut tissue produces more PepT1, so oral KPV may preferentially concentrate where inflammation is worst (Dalmasso et al. 2008, Gastroenterology).

NF-kB is the master switch that turns on inflammatory gene expression. Preclinical work reports that KPV reduces how long this switch stays "on" and how many inflammatory signals are produced — without the broad immunosuppression of corticosteroids.

Some older articles claim KPV acts on melanocortin receptors. This is incorrect. The 2008 Dalmasso paper showed no melanocortin-receptor signaling, and follow-up work in receptor-knockout mice confirmed KPV still works without those receptors. KPV does not cause tanning or pigmentation changes and should not be confused with melanotan compounds.

KPV is researched mainly for anti-inflammatory and gut-barrier models. Because no human trial has been completed, eligibility framing is conservative.

Generally outside research-planning scope: pregnancy and breastfeeding (no safety data), known hypersensitivity to peptide compounds, and active complex infectious disease without clinician oversight (because of overlapping inflammatory and antimicrobial signaling).

Caution areas: active autoimmune disease on prescribed immunomodulators (the interaction has not been studied), and IBD or other inflammatory bowel conditions managed with prescription therapy. KPV should not replace prescribed medication and should be discussed with the treating clinician.

Quality-control caution: KPV is sold as research-use peptide outside FDA-approved channels. Source quality, COA verification, and storage handling vary widely between suppliers.

KPV is generally reported as well-tolerated in animal studies and in community use, but no formal human safety trial has been completed. Long-term safety data does not exist.

Commonly reported effects (community-level, not trial data): mild and transient injection-site irritation, occasional mild headache, and occasional GI upset at higher oral doses.

Pigmentation: KPV is generally modeled as non-pigmenting. It does not bind the melanocortin receptors that drive melanotan-style tanning.

Immune profile: KPV dials down specific inflammatory pathways (notably NF-kB) rather than broadly suppressing the immune system. In animal work this has not produced the infection-susceptibility profile seen with corticosteroids — but this distinction has not been confirmed in human trials.

Quality-control risk: As with any research-use peptide, contamination, underdosing, or incorrect labeling are real risks. Use COA-verified suppliers and inspect every reconstituted vial for clarity before use.

General cautions: Avoid in pregnancy/breastfeeding. Discuss with a clinician if you have active autoimmune disease, complex infectious disease, or are taking prescribed immunomodulators.

There is no human trial defining a KPV timeline. Animal studies measure inflammatory markers within days to weeks. Community-reported timelines should be treated as anecdotal.

What to monitor (for research review): symptom-level changes, injection-site condition, oral GI tolerance, and any new symptoms that prompt review with a clinician. Lab panels are not standard for KPV review because there is no trial-defined monitoring protocol.

Stopping points: persistent injection-site reactions that worsen rather than improve, unexpected GI symptoms on oral protocols, or any symptom that warrants clinician evaluation.

The gut-inflammation findings — particularly the PepT1 transport discovery — are the strongest part of the KPV literature. They are still preclinical. No human study has yet confirmed how effective KPV is in people, what an optimal dose looks like, or what the long-term safety profile is.

As of May 2026, KPV is not FDA-approved for any indication. No pharmaceutical company holds an approved KPV drug.

On April 15, 2026, the FDA published a notice that twelve peptide bulk drug substances would be removed from Category 2 (the "significant safety concerns" list) effective April 22, 2026, because the original nominators withdrew their nominations. KPV was on that list.

Removal from Category 2 does not place KPV on Category 1 and does not constitute FDA approval. The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to consult on the potential inclusion of KPV acetate and KPV (free base) on the 503A bulks list at its meeting on July 23, 2026. Until that review concludes and the FDA acts on it, compounding pharmacies remain in a transitional position.

WADA status: KPV is not a named WADA-prohibited substance. The relevant alpha-MSH-derived compounds covered under WADA rules are different molecules.

Sources for this section: FDA bulk substances list update (April 22, 2026 revision) and the SSRP Institute April 15, 2026 announcement. See the Sources & Research section for direct links.

KPV is most often compared to BPC-157 (a repair-focused peptide) and to alpha-MSH (the full-length hormone KPV is derived from). The short version: KPV is for inflammation, BPC-157 is for repair, and alpha-MSH is the parent hormone with broader effects.

KPV should not be confused with melanotan compounds. Pigmentation is not part of KPV's profile.

KPV pairs naturally with repair- and skin-focused peptides. The most-discussed combinations are below.

KPV is usually discussed in inflammation, gut, immune, and skin research. Monitoring focuses on broad inflammatory context, but labs may not capture local skin or gut response.